1748 related articles for article (PubMed ID: 33762733)
1. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
[TBL] [Abstract][Full Text] [Related]
2. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD122 antibody restores specific CD8
Lacotte S; Slits F; Moeckli B; Peloso A; Koenig S; Tihy M; El Hajji S; Gex Q; Rubbia-Brandt L; Toso C
Oncoimmunology; 2023; 12(1):2184991. PubMed ID: 36891258
[TBL] [Abstract][Full Text] [Related]
4. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
5. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
9. Metformin treatment rescues CD8
Wabitsch S; McCallen JD; Kamenyeva O; Ruf B; McVey JC; Kabat J; Walz JS; Rotman Y; Bauer KC; Craig AJ; Pouzolles M; Phadke I; Catania V; Green BL; Fu C; Diggs LP; Heinrich B; Wang XW; Ma C; Greten TF
J Hepatol; 2022 Sep; 77(3):748-760. PubMed ID: 35378172
[TBL] [Abstract][Full Text] [Related]
10. Auto-aggressive CXCR6
Dudek M; Pfister D; Donakonda S; Filpe P; Schneider A; Laschinger M; Hartmann D; Hüser N; Meiser P; Bayerl F; Inverso D; Wigger J; Sebode M; Öllinger R; Rad R; Hegenbarth S; Anton M; Guillot A; Bowman A; Heide D; Müller F; Ramadori P; Leone V; Garcia-Caceres C; Gruber T; Seifert G; Kabat AM; Mallm JP; Reider S; Effenberger M; Roth S; Billeter AT; Müller-Stich B; Pearce EJ; Koch-Nolte F; Käser R; Tilg H; Thimme R; Boettler T; Tacke F; Dufour JF; Haller D; Murray PJ; Heeren R; Zehn D; Böttcher JP; Heikenwälder M; Knolle PA
Nature; 2021 Apr; 592(7854):444-449. PubMed ID: 33762736
[TBL] [Abstract][Full Text] [Related]
11. Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
Kara-Ali GH; Cano L; Dion S; Imerzoukene G; Hamon A; Simoes Eugénio M; Piquet-Pellorce C; Ghukasyan G; Samson M; Le Seyec J; Dimanche-Boitrel MT
Int J Cancer; 2024 Jun; 154(11):1999-2013. PubMed ID: 38308587
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.
Lombardi R; Piciotti R; Dongiovanni P; Meroni M; Fargion S; Fracanzani AL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269846
[TBL] [Abstract][Full Text] [Related]
13. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
Ma C; Kesarwala AH; Eggert T; Medina-Echeverz J; Kleiner DE; Jin P; Stroncek DF; Terabe M; Kapoor V; ElGindi M; Han M; Thornton AM; Zhang H; Egger M; Luo J; Felsher DW; McVicar DW; Weber A; Heikenwalder M; Greten TF
Nature; 2016 Mar; 531(7593):253-7. PubMed ID: 26934227
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
15. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Li M; Wang L; Cong L; Wong CC; Zhang X; Chen H; Zeng T; Li B; Jia X; Huo J; Huang Y; Ren X; Peng S; Fu G; Xu L; Sung JJY; Kuang M; Li X; Yu J
Hepatology; 2024 Mar; 79(3):560-574. PubMed ID: 37733002
[TBL] [Abstract][Full Text] [Related]
16. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
17. State of CD8
Zhong X; Lv M; Ma M; Huang Q; Hu R; Li J; Yi J; Sun J; Zhou X
Biomed Pharmacother; 2023 Sep; 165():115131. PubMed ID: 37429231
[TBL] [Abstract][Full Text] [Related]
18. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
19. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
Yahoo N; Dudek M; Knolle P; Heikenwälder M
J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]